

## SUBSTANTIAL SHAREHOLDERS

So far as our Directors are aware, immediately following the completion of the [REDACTED] and conversion of our Domestic Shares and Unlisted Foreign Shares into H Shares (assuming that the [REDACTED] is not exercised), the following persons are expected to have or be deemed or taken to have an interest and/or a short position in the Shares or underlying shares of our Company, which would be required to be disclosed to us and the Stock Exchange pursuant to the provisions of Divisions 2 and 3 of Part XV of the SFO or will, directly or indirectly, be interested in 10% or more of the nominal value of share capital carrying rights to vote in all circumstances at the general meetings of the Company or any other members of the Group:

### LONG POSITIONS IN THE SHARES OF THE COMPANY

Name of substantial shareholder	Nature of interest	Description of Shares	Shares held as of the Latest Practicable Date		Shares held immediately following the completion of the [REDACTED] and Conversion of Domestic Shares and Unlisted Foreign Shares into H Shares (assuming the [REDACTED] is not exercised)	
			Number	Percentage in the total issued share capital <sup>(6)</sup>	Number	Percentage in the total issued share capital
Mr. LIU Gexin <sup>(1)</sup>	Interest in a controlled corporation	Domestic Shares	145,555,685	75.27%	136,555,685	[REDACTED]%
		H Shares	-	-	9,000,000	[REDACTED]%
Kelun Pharmaceutical <sup>(1)</sup>	Beneficial owner	Domestic Shares	115,555,685	59.75%	115,555,685	[REDACTED]%
		H Shares	-	-	-	-
	Interest in a controlled corporation <sup>(2)</sup>	Domestic Shares	30,000,000	15.51%	21,000,000	[REDACTED]%
MSD <sup>(3)</sup>	Beneficial owner	H Shares	-	-	9,000,000	[REDACTED]%
		Unlisted Foreign Shares	13,443,693	6.95%	-	-
		H Shares	-	-	13,443,693	[REDACTED]%

*Notes:*

- (1) Mr. LIU Gexin, the actual controller of Kelun Pharmaceutical, was deemed to be interested in the Shares of which are exercisable by Kelun Pharmaceutical under the SFO. Please see “Relationship with Our Controlling Shareholders – Overview” for details.
- (2) As of the Latest Practicable Date, our Employee Incentive Platforms, namely Kelun Huicai, Kelun Huineng, Kelun Huizhi and Kelun Huide, in aggregate, held 30,000,000 Domestic Shares of our Company. Please see “Appendix VII – Statutory and General Information – D. Employee Incentive Scheme” for details. Kelun Jingchuan, a wholly-owned subsidiary of Kelun Pharmaceutical, is the general partner of each of our Employee Incentive Platforms. Therefore, Kelun Pharmaceutical was entitled to exercise the voting rights attaching to the Shares held by our Employee Incentive Platforms.
- (3) As of the Latest Practical Date, MSD held 13,443,693 Unlisted Foreign Shares of our Company. MSD is a wholly-owned subsidiary of Merck & Co., Inc., a company listed on the New York Stock Exchange (stock code: MRK). Therefore, Merck & Co., Inc. was deemed to be interested in the Shares held by MSD under the SFO.

## SUBSTANTIAL SHAREHOLDERS

---

Save as otherwise disclosed herein, our Directors are not aware of any persons who will, immediately following the [REDACTED] (assuming the [REDACTED] is not exercised), have any interests and/or short positions in the Shares or underlying shares of our Company which would fall to be disclosed to the Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO or, will be, directly or indirectly, interested in 10% or more of the nominal value of share capital carrying rights to vote in all circumstances at general meetings of our Company or any other member of our Group.

We are not aware of any arrangement which may result in any change of control in our Company at any subsequent date.